You are about to leave this site and are being redirected to another site. Would you like to leave this site?

BAVENCIO is a PD-L1 inhibitor that activates dual immune function1

moa-chartmoa-chart

moa-chart
moa-chart

Tap to zoom in

Preclinical and in vitro data may not necessarily correlate with clinical outcomes.

ADAPTIVE IMMUNE RESPONSE

BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response by blocking the interaction of PD-L1 with PD-1 receptors in preclinical models

INNATE IMMUNE RESPONSE

BAVENCIO has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro

Recommended dosage

 

Premedication

 

Reference: 1. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells.
Cancer Immunol Res. 2015;3(10):1148-1157.